Bridge to Life™ Showcases Innovative HOPE Clinical Data at 2025 Transplant Congress

Bridge to Life™ Presents New Clinical Insights on HOPE at World Transplant Congress 2025



On July 15, 2025, Bridge to Life™ Ltd., a world leader in organ preservation and perfusion technology, announced it will showcase significant clinical trial results at the upcoming World Transplant Congress (WTC), taking place from August 2 to 6, 2025, in San Francisco. This congress, a joint event of the American Society of Transplantation (AST), American Society of Transplant Surgeons (ASTS), and The Transplantation Society (TTS), aims to highlight advancements in organ transplantation and preservation technology.

One of the major highlights of the event will be the presentation of 12 months of follow-up data from the pivotal Bridge to HOPE trial. This research provides valuable insights into both the clinical and economic impacts of Hypothermic Oxygenated Perfusion (HOPE) in liver transplantation. The data will be presented across multiple oral sessions, including a plenary session, underscoring Bridge to Life's leadership in the field of transplantation science.

Scheduled Presentations for WTC 2025



  • - Plenary Session
Title: Hypothermic-Oxygenated and Normothermic Machine Perfusion: A Risk-Matched Post-Hoc Comparison of the Bridge to Hope Randomized Trial with Prospectively Collected Institutional Outcomes
Date: August 4, 2025
Time: 10:30 AM - 10:45 AM PT
Presenter: Chase J. Wehrle, MD, Cleveland Clinic, Cleveland, OH (ILTS 2025 Young Investigators Award Winner)

  • - Poster Presentations
- Title: Impact of Hypothermic Oxygenated Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation: An Age- Stratified Analysis
Date: August 4, 2025
Time: 3:30 PM - 4:30 PM PT
Presenter: Marco Maria Pascale, MD, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.

- Title: Mitochondrial Injury and Function Comparing Hypothermic and Normothermic Machine Perfusion of Human Livers
Date: August 5, 2025
Time: 3:30 PM - 4:30 PM PT
Presenter: Omer Faruk Karakaya, MD, Department of Inflammation and Immunity, Lerner Research Institute - Cleveland Clinic, Cleveland, OH.

Oral Abstract Presentations


- Title: Economic Assessment of Hypothermic Oxygenated Machine Perfusion in Liver Transplantation
Date: August 5, 2025
Time: 5:26 PM - 5:35 PM PT
Presenter: David Axelrod, MD, University Hospitals Cleveland Medical Center, OH.

- Title: Decreased Rejection Severity with Hypothermic Oxygenated Perfusion: Sub Analysis from a Pivotal Multicenter Trial of HOPE for Liver Transplantation
Date: August 6, 2025
Time: 9:20 AM - 9:29 AM PT
Presenter: David J. Reich, MD, FACS, Drexel University, Philadelphia, PA.

Spotlight on Novel Approaches


Moreover, a last-minute oral summary presentation titled Novel Approach to Viability Assessment of Split Liver Grafts Using Hypothermic Oxygenated Perfusion is set for August 3, 2025, by Geofia Crasta, MD, of the Cleveland Clinic - Lerner Research Institute. This will further emphasize innovative methodologies in assessing liver transplant viability, showcasing how HOPE techniques can transform donor organ viability assessments.

Symposium on HOPE


Bridge to Life™ will also sponsor a symposium on August 4, 2025, from 7:00 AM to 8:00 AM PDT, titled Hypothermic Oxygenated Perfusion (HOPE): From Science to Clinical Impact, moderated by Garret Roll, MD, of the University of California San Francisco. This event will feature discussions led by experts, including David Axelrod, MD, and Andrea Schlegel, MD, focusing on the practical implications of HOPE in transplant settings.

About Bridge to Life™ Ltd


As a market leader in organ preservation solutions, Bridge to Life™ Ltd. is renowned for its high-quality products, including Belzer UW®, EasiSlush®, and the HOPE system, VitaSmart™. With a strong emphasis on product quality, innovation, and accessibility, the company collaborates with top transplant centers and organ procurement organizations globally. It's worth noting that VitaSmart™ is CE marked and available in several markets outside the United States, pending FDA approval in the U.S.

The WTC 2025 is set to be a monumental event for advancements in transplantation, with Bridge to Life leading the charge in novel preservation technologies that hold promise for countless patients awaiting transplants.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.